Stay updated with breaking news from Adapted. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccineThe Omicron BA.1-adapted bivalent COVID-19 vaccine combines
Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccinesPfizer-BioNTech Omicron BA.4/BA.5 bivalent vaccine combines 15-µg of mRNA encoding the wild-type
Authorization based on clinical, pre-clinical and manufacturing data for Omicron-adapted bivalent vaccines Pfizer-BioNTech Omicron BA.4/BA.5 Bivalent Vaccine combines 15-g of mRNA encoding
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) said Friday that they have completed a submission to the European Medicines Agency or EMA for a booster dose of an Omicron BA.4/BA.5-adapted
Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4/5-adapted bivalent vaccines will be available in the